TY - JOUR
T1 - Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure
T2 - a propensity score matched study from the APASL ACLF Research Consortium (AARC)
AU - APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party
AU - Sharma, Sanchit
AU - Agarwal, Samagra
AU - Saraya, Anoop
AU - Choudhury, Ashok
AU - Mahtab, Mamun Al
AU - Alam, Mohd Shahinul
AU - Saigal, Sanjiv
AU - Kim, Dong Joon
AU - Eapen, C. E.
AU - Goel, Ashish
AU - Ning, Qin
AU - Devarbhavi, Harshad
AU - Singh, Virendra
AU - Shukla, Akash
AU - Hamid, Saeed
AU - Hu, Jinhua
AU - Tan, Soek Siam
AU - Arora, Anil
AU - Sahu, Manoj Kumar
AU - Rela, Mohd
AU - Jothimani, Dinesh
AU - Rao, P. N.
AU - Kulkarni, Anand
AU - Ghaznian, Hashmik
AU - Lee, Guan Huei
AU - Zhongping, Duan
AU - Sood, Ajit
AU - Goyal, Omesh
AU - Lesmana, Laurentius A.
AU - Lesmana, Rinaldi C.
AU - Treeprasertsuk, Sombat
AU - Yuemin, Nan
AU - Shah, Samir
AU - Tao, Han
AU - Dayal, V. M.
AU - Shaojie, Xin
AU - Karim, Fazal
AU - Abbas, Zaigham
AU - Sollano, Jose D.
AU - Kalista, Kemal Fariz
AU - Shreshtha, Ananta
AU - Payawal, Diana
AU - Omata, Masao
AU - Sarin, Shiv Kumar
AU - Sarin, Shiv Kumar
AU - Sharma, Manoj K.
AU - Maiwall, Rakhi
AU - Al Mahtab, Mamun
AU - Jafri, Wasim
AU - Abbas, Zaigham
N1 - Funding Information:
APASL ACLF working Party Collaborators Detail: Shiv Kumar Sarin, Ashok Choudhury, Manoj K. Sharma, Rakhi Maiwall, Mamun Al Mahtab, Salimur Rahman, Sanjiv Saigal, Neeraj Saraf, A. S. Soin, Harshad Devarbhavi, Dong Joon Kim, R. K. Dhiman, Ajay Duseja, Sunil Taneja, C. E. Eapen, Ashish Goel, Q. Ning, Tao Chen, Ke Ma, Z. Duan, Chen Yu, Sombat Treeprasertsuk, S. S. Hamid, Amna S. Butt, Wasim Jafri, Akash Shukla, Vivek Saraswat, Soek Siam Tan, Ajit Sood, Vandana Midha, Omesh Goyal, Hasmik Ghazinyan, Anil Arora, Jinhua Hu, Manoj Sahu, P. N. Rao, Guan H. Lee, Seng G. Lim, Laurentius A. Lesmana, Cosmas Rinaldi Lesmana, Samir Shah, V. G. Mohan Prasad, Diana A. Payawal, Zaigham Abbas, A. Kadir Dokmeci, Jose D. Sollano, Gian Carpio, Ananta Shresta, G. K. Lau, Md. Fazal Karim, Gamal Shiha, Rino Gani, Kemal Fariz Fariz Kalista, Man-Fung Yuen, Seema Alam, Rajeev Khanna, Vikrant Sood, Bikrant Bihari Lal, Viniyendra Pamecha, Ankur Jindal, V. Rajan, Vinod Arora, Osamu Yokosuka, Madunil A. Niriella, Hai Li, Xiaolong Qi, Atsushi Tanaka, Satoshi Mochida, Dominic Ray Chaudhuri, Ed Gane, Khin Maung Win, Wei Ting Chen, Mohd Rela, Dharmesh Kapoor, Amit Rastogi, Pratibha Kale, Archana Rastogi, Chhagan Bihari Sharma, Meenu Bajpai, Virender Singh, Madhumita Premkumar, Sudhir Sudhir, A. Olithselvan, Cyriac Abby Philips, Anshu Srivastava, Surender K. Yachha, Zeeshan Ahmad Wani, B. R. Thapa, Anoop Saraya, Shalimar, Ashish Kumar, Manav Wadhawan, Subash Gupta, Kaushal Madan, Puja Sakhuja, Vivek Vij, Barjesh C. Sharma, Hitendra Garg, Vishal Garg, Chetan Kalal, Lovkesh Anand, Tanmay Vyas, Rajan P. Mathur, Guresh Kumar, Priyanka Jain, Samba Siva Rao Pasupuleti, Yogesh K. Chawla, Abhijit Chowdhury, Shahinul Alam, Do Seon Song, Jin Mo Yang.
Publisher Copyright:
© 2022, Asian Pacific Association for the Study of the Liver.
PY - 2022/10
Y1 - 2022/10
N2 - Background and aims: Limited data exist regarding outcomes of acute variceal bleeding (AVB) in patients with acute-on-chronic liver failure (ACLF), especially in those with hepatic failure. We evaluated the outcomes of AVB in patients with ACLF in a multinational cohort of APASL ACLF Research Consortium (AARC). Methods: Prospectively maintained data from AARC database on patients with ACLF who developed AVB (ACLF-AVB) was analysed. This data included demographic profile, severity of liver disease, and rebleeding and mortality in 6 weeks. These outcomes were compared with a propensity score matched (PSM) cohort of ACLF matched for severity of liver disease (MELD, AARC score) without AVB (ACLF without AVB). Results: Of the 4434 ACLF patients, the outcomes in ACLF-AVB (n = 72) [mean age—46 ± 10.4 years, 93% males, 66% with alcoholic liver disease, 65% with alcoholic hepatitis, AARC score: 10.1 ± 2.2, MELD score: 34 (IQR: 27–40)] were compared with a PSM cohort selected in a ratio of 1:2 (n = 143) [mean age—44.9 ± 12.5 years, 82.5% males, 48% alcoholic liver disease, 55.7% alcoholic hepatitis, AARC score: 9.4 ± 1.5, MELD score: 32 (IQR: 24–40)] of ACLF-without AVB. Despite PSM, ACLF patients with AVB had a higher baseline HVPG than without AVB (25.00 [IQR: 23.00–28.00] vs. 17.00 [15.00–21.75] mmHg; p = 0.045). The 6-week mortality in ACLF patients with or without AVB was 70.8% and 53.8%, respectively (p = 0.025). The 6-week rebleeding rate was 23% in ACLF-AVB. Presence of ascites [hazard ratio (HR) 2.2 (95% CI 1.03–9.8), p = 0.026], AVB [HR 1.9 (95% CI 1.2–2.5, p = 0.03)], and MELD score [HR 1.7 (95% CI 1.1–2.1), p = 0.001] independently predicted mortality in the overall ACLF cohort. Conclusion: Development of AVB confers poor outcomes in patients with ACLF with a high 6-week mortality. Elevated HVPG at baseline represents a potential risk factor for future AVB in ACLF.
AB - Background and aims: Limited data exist regarding outcomes of acute variceal bleeding (AVB) in patients with acute-on-chronic liver failure (ACLF), especially in those with hepatic failure. We evaluated the outcomes of AVB in patients with ACLF in a multinational cohort of APASL ACLF Research Consortium (AARC). Methods: Prospectively maintained data from AARC database on patients with ACLF who developed AVB (ACLF-AVB) was analysed. This data included demographic profile, severity of liver disease, and rebleeding and mortality in 6 weeks. These outcomes were compared with a propensity score matched (PSM) cohort of ACLF matched for severity of liver disease (MELD, AARC score) without AVB (ACLF without AVB). Results: Of the 4434 ACLF patients, the outcomes in ACLF-AVB (n = 72) [mean age—46 ± 10.4 years, 93% males, 66% with alcoholic liver disease, 65% with alcoholic hepatitis, AARC score: 10.1 ± 2.2, MELD score: 34 (IQR: 27–40)] were compared with a PSM cohort selected in a ratio of 1:2 (n = 143) [mean age—44.9 ± 12.5 years, 82.5% males, 48% alcoholic liver disease, 55.7% alcoholic hepatitis, AARC score: 9.4 ± 1.5, MELD score: 32 (IQR: 24–40)] of ACLF-without AVB. Despite PSM, ACLF patients with AVB had a higher baseline HVPG than without AVB (25.00 [IQR: 23.00–28.00] vs. 17.00 [15.00–21.75] mmHg; p = 0.045). The 6-week mortality in ACLF patients with or without AVB was 70.8% and 53.8%, respectively (p = 0.025). The 6-week rebleeding rate was 23% in ACLF-AVB. Presence of ascites [hazard ratio (HR) 2.2 (95% CI 1.03–9.8), p = 0.026], AVB [HR 1.9 (95% CI 1.2–2.5, p = 0.03)], and MELD score [HR 1.7 (95% CI 1.1–2.1), p = 0.001] independently predicted mortality in the overall ACLF cohort. Conclusion: Development of AVB confers poor outcomes in patients with ACLF with a high 6-week mortality. Elevated HVPG at baseline represents a potential risk factor for future AVB in ACLF.
KW - Acute variceal bleeding
KW - Alcoholic hepatitis
KW - Hepatic failure
KW - Hepatic venous pressure gradient
KW - Infections
KW - Organ failure
KW - Portal hypertension
KW - Portal pressure
KW - Rebleeding
KW - Varices
UR - http://www.scopus.com/inward/record.url?scp=85134544298&partnerID=8YFLogxK
U2 - 10.1007/s12072-022-10372-1
DO - 10.1007/s12072-022-10372-1
M3 - Article
C2 - 35851437
AN - SCOPUS:85134544298
SN - 1936-0533
VL - 16
SP - 1234
EP - 1243
JO - Hepatology International
JF - Hepatology International
IS - 5
ER -